Can-Fite BioPharma

Can-Fite to develop CF102 for the treatment of liver cancer

Published in Lab Business Week, November 12th, 2006

Can-Fite BioPharma (CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced that the second drug in its development pipeline, CF102, will be intended for treatment of liver cancer (hepatocellular carcinoma).

Preclinical trials conducted by the company have shown that CF102 performs well in the inhibition of liver cancer in animal models. In addition, it was proven that the A3 Adenosine receptor, which is the drug target, is over-expressed in liver cancer tumors. The company has recently developed an assay that enables a blood test to determine the receptor level before treatment initiation.

Liver cancer attacks approximately...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-11-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry